Skip to main content

Table 2 Specific characteristics of BM patients (n = 12)

From: Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

Age (median, range) 66 (45-88)  
  n %
Number of extracerebral metastatic sites at occurrence of BM   
   - 1 7 58.3
   - 2 2 16.7
   - ≥ 3   
Location of extracerebral metastases   
Lung 8 66.7
Liver 2 16.7
Bone 2 16.7
LN 3 25
other 5 41.7
Time from primary tumor to occurrence of BM   
< 2 years 9 75
> 2 years 3 25
Number of brain lesions   
1 6 50
2 4 33.3
> 2 2 16.7
Location of BM metastases   
   - frontal 4 33.3
   - parietal 2 16.7
   - cerebellar 4 33.3
   - temporal 1 8.3
   - dissiminated 1 8.3
Lesion size   
1cm 1 8.3
1-2cm 2 16.7
> 2cm 9 75
CNS symptoms   
Yes 10 83.3
No 2 16.7
   - psychiatric 1 8.3
   - vertigo 2 16.7
   - headache 5 41.7
   - ataxia 3 25
   - hemiplegia 1 8.3
Local treatment for BM   
   - surgery 2 16.7
   - surgery+ SR 1 8.3
   - surgery+WBRT 2 16.7
   - SR 2 16.7
   - SR+WBRT 2 16.7
   - WBRT 3 25
First targeted agent after local control of BM   
   - Bevacizumab 2 16.7
   - Sunitinib 7 58.3
   - Sorafenib 2 16.7
   - Temsirolimus 1 8.3